VTGN insider transaction filings
Vistagen Therapeutics, Inc. — 27 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-31. Screen VTGN transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-31 | 4 | Williamson Douglas J — Director | Grant/award (A): 40,826 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Adler Reid G. — Chief Legal Officer | Grant/award (A): 36,818 @ $0.19 | EDGAR |
| 2026-07-02 | 4 | Tressler Nick B. — Chief Financial Officer | Grant/award (A): 11,712 @ $0.19 | EDGAR |
| 2026-07-02 | 4 | Singh Shawn — President and CEO, Director | Grant/award (A): 36,818 @ $0.19 | EDGAR |
| 2026-05-19 | 4 | Angelov Angel S — Chief Medical Officer | Grant/award (A): 150,000 (derivative) | EDGAR |
| 2026-04-09 | 4 | Cote Elissa S. — Chief Corp Development Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Prince Joshua S. — Chief Operating Officer | Grant/award (A): 18,752 (derivative) @ $0 · Grant/award (A): 56,248 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Adler Reid G. — Chief Legal Officer | Grant/award (A): 18,753 (derivative) @ $0 · Grant/award (A): 56,247 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Tressler Nick B. — Chief Financial Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Singh Shawn — President and CEO, Director | Grant/award (A): 3,732 (derivative) @ $0 · Grant/award (A): 71,268 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Prince Joshua S. — Chief Operating Officer | Grant/award (A): 4,386 @ $0.56 | EDGAR |
| 2025-12-04 | 4 | Tressler Nick B. — Chief Financial Officer | Grant/award (A): 150,000 (derivative) | EDGAR |
| 2025-11-04 | 4 | Edick Paul R — Director | Grant/award (A): 35,200 (derivative) | EDGAR |
| 2025-09-11 | 4 | Rotunno Mary L. — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-09-11 | 4 | FitzPatrick Margaret M — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-09-11 | 4 | Curley Joanne — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-09-11 | 4 | Cunningham Ann Michelle — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-09-11 | 4 | SAXE JON S — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Prince Joshua S. — Chief Operating Officer | Grant/award (A): 4,882 @ $1.70 | EDGAR |
| 2025-07-01 | 4 | Adler Reid G. — Chief Legal Officer | Grant/award (A): 7,541 @ $1.70 | EDGAR |
| 2025-07-01 | 4 | Anderson Cynthia Lynn — CHIEF FINANCIAL OFFICER | Grant/award (A): 6,617 @ $1.70 | EDGAR |
| 2025-07-01 | 4 | Singh Shawn — President and CEO, Director | Grant/award (A): 7,541 @ $1.70 | EDGAR |
| 2025-06-25 | 4 | Cote Elissa S. — Chief Corp Development Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Anderson Cynthia Lynn — CHIEF FINANCIAL OFFICER | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Prince Joshua S. — Chief Operating Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Adler Reid G. — Chief Legal Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Singh Shawn — President and CEO, Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Vistagen Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-05 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-07-31 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-09 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VTGN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →